MedCity News February 1, 2022
The Study to Accelerate Information of Molecular Signatures (AIMS) found RA patients whose treatment was guided by the PrismRA blood test had three times better clinical responses compared to patients that didn’t.
Thus far, the promise of precision medicine has been directed largely toward the field of oncology in terms of recommending personalized treatments based on molecular diagnostics tests. But increasingly, the knowledge of if specific individuals will or won’t benefit from certain treatments is informing providers in a broader set of diseases.
On Monday, Scipher Medicine, a precision immunology company based in Waltham, Massachusetts, announced clinical results of a study that examined treatment and outcomes for 212 rheumatoid arthritis (RA) patients whose healthcare providers used its PrismRA blood test....
Today's Sponsors
Today's Sponsor